Guangzhou Link Health Pharma

Link Health Pharma is a leading biopharmaceutical company based in Guangzhou, China, specializing in the development and commercialization of innovative therapies for the Chinese and global markets. Founded in 2009, the company operates through a hybrid model of internal R&D and strategic in-licensing, bridging the gap between Western drug discovery and Chinese clinical development. Its primary therapeutic focus areas include dermatology, respiratory diseases, oncology, and the central nervous system. The company's lead program, Tapinarof (LHS-001), is a first-in-class aryl hydrocarbon receptor modulating agent for the treatment of psoriasis. Link Health maintains a robust pipeline of small molecules and biologics aimed at addressing significant unmet medical needs in China.